Prelude Therapeutics Inc (NAS:PRLD)
$ 3.82 0.115 (3.1%) Market Cap: 209.83 Mil Enterprise Value: 18.95 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 38/100

Prelude Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 12:00PM GMT
Release Date Price: $30.72 (-1.85%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Good morning, everyone, and welcome to the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover both U.S. and European biopharma names here at the firm. It's my pleasure to be hosting Prelude Therapeutics in a fireside chat this morning. And with that, let me welcome the company. We've got company's CEO, Kris Vaddi; CFO, Brian Piper; and Chief Business Officer -- I'm sorry, and Christopher Pierce, the company's Chief Business Officer.

So with that, good morning, gentlemen, welcome to the conference, and we look forward to many more years of your participation. With that, for those who are perhaps newer to the Prelude story and you are recently -- relatively recently IPOed company, perhaps there are some who are unfamiliar with the Prelude story. So with that, maybe, Kris, if I could turn it over to you. And if you could just tell us a little bit more about the company, kind of maybe a little bit of its history and what you feel are kind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot